Intuitive Surgical is still grappling with a slowdown in demand for bariatric surgeries due to the rise of GLP-1 medications like Ozempic, Chief Executive Gary Guthart tells an audience at the JPMorgan Healthcare Conference. “The deceleration hasn’t stopped,” he says. “We’re still growing, but it’s decelerating.” What that means for the longterm outlook for bariatric weight-loss surgeries is unclear. Company executives have previously said they expect the GLP-1-related slowdown to only be short term. Shares rise 10%.